Skip to main content
Premium Trial:

Request an Annual Quote

Carl Balezentis and Rob Martienssen

Premium

Enzo Biochem appointed Carl Balezentis as president of Enzo Life Sciences, its wholly owned subsidiary, the company said last week.

Formerly, Balezentis was chief executive officer of Lark Technologies prior to its acquisition by Genaissance Pharmaceuticals. After the acquisition, he joined Genaissance as a senior vice-president. Prior to Lark, he was director of business development at Sigma-Aldrich's life sciences division. He was vice president of sales and marketing at Genosys Biotechnologies prior to its acquisition by Sigma-Aldrich.

Balezentis was a director of marketing at Perceptive Scientific Instruments before its acquisition by International Remote Imaging Systems, and a group leader for human identity products at Applied Biosystems.



Orion Genomics co-founder Rob Martienssen has been appointed a fellow of the Royal Society of London, Orion said this week.

Past fellows include Isaac Newton, Charles Darwin, Albert Einstein, and James Watson, Orion said. Watson, like Martienssen, is also a member of Orion's scientific advisory board.

Martienssen holds a BA in natural sciences from Cambridge University and a PhD from the Plant Breeding Institute and Cambridge University.

He currently serves on the faculty at Cold Spring Harbor Laboratory.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.